West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million and diluted earnings per share of $3.02, reflecting growth compared to the prior-year period. Driven by strong execution in its Proprietary Products segment, the company raised its full-year net sales and adjusted-diluted EPS guidance ranges.
Q3 2026 net sales reached $874.5 million, up 8.7% year-over-year, with diluted EPS of $3.02.
Full-year 2026 net sales guidance was increased to a range of $3.41 billion to $3.42 billion.
Full-year 2026 adjusted-diluted EPS guidance was raised to a range of $9.38 to $9.48.
The company repurchased $231 million of stock in the third quarter, bringing year-to-date repurchases to $685 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From West Pharmaceutical Services's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.07B
+6.3%
$6.79
+1.5%
16.1%
FY2024
$2.89B
-1.9%
$6.69
-15.1%
17.0%
FY2023
$2.95B
+2.2%
$7.88
+1.9%
20.1%
FY2022
$2.89B
+2.0%
$7.73
-10.8%
20.3%
FY2021
$2.83B
+31.9%
$8.67
+89.7%
23.4%
Frequently asked questions
When is West Pharmaceutical Services's next earnings date?
West Pharmaceutical Services has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did West Pharmaceutical Services earn last quarter?
For the quarter ended Sep 2026, West Pharmaceutical Services reported diluted EPS of $3.02 (+57.3% year over year) on revenue of $874.50M (+8.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.